Company profile
BIOMEA FUSION, INC.
NASDAQ:BMEABiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ICOVAMENIB | phase2 | — | 7 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05918692 | phase1 | completed | 2023-07-26 | 2026-01-01 | Biomea Fusion Inc. | A Phase 1 Study of BMF-500 in Adults With Acute Leukemia |
| NCT07254286 | phase1 | completed | 2025-09-11 | 2026-01-14 | Biomea Fusion Inc. | Food Effect Study in Healthy Volunteers |
| NCT06152042 | phase2 | completed | 2023-12-28 | 2025-05-20 | Biomea Fusion Inc. | Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus |
| NCT07502508 | phase2 | recruiting | 2026-04-30 | 2027-06-01 | Biomea Fusion Inc. | Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy |
| NCT07502495 | phase2 | active_not_recruiting | 2026-03-27 | 2027-03-01 | Biomea Fusion Inc. | Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets |
FDA applications (0)
No records yet.